(PDF) Pss15 - Budget Impact Analysis of Apremilast in

Pss15 - Budget Impact Analysis of Apremilast in Patients With Moderate-To-Severe Plaque Psoriasis in Greece

Value in Health - United Kingdom

doi 10.1016/j.jval.2018.09.2515

Full Text

Abstract

Available in full text

Categories

Occupational Health

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

Costs of Treatment in Patients With Moderate to Severe Plaque Psoriasis

Archives of Dermatology

English

Pss13 - Budget Impact Analysis of Apremilast in Patients With Active Psoriatic Arthritis in Greece

Value in Health

Occupational Health

English

Population Pharmacokinetics of Brodalumab in Patients With Moderate to Severe Plaque Psoriasis

Basic and Clinical Pharmacology and Toxicology

English

Pharmacokinetics and Safety of Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: Results From a Phase 2 Open-Label Study

Journal of the American Academy of Dermatology

English

The Experience of Pain and Redness in Patients With Moderate to Severe Plaque Psoriasis

Journal of Dermatological Treatment

English

Pss32 - Cost-Effectiveness of Brodalumab for the Treatment of Moderate to Severe Plaque Psoriasis in Greece

Value in Health

Occupational Health

English

Immunogenicity of Guselkumab Is Not Clinically Relevant in Patients With Moderate-To-Severe Plaque Psoriasis

Journal of Investigative Dermatology

Molecular Biology

English

New Polymorphisms Associated With Response to Anti-TNF Drugs in Patients With Moderate-To-Severe Plaque Psoriasis

Pharmacogenomics Journal

Molecular Medicine

English

Randomized, Controlled Study of Bleselumab (ASKP1240) Pharmacokinetics and Safety in Patients With Moderate-To-Severe Plaque Psoriasis

Biopharmaceutics and Drug Disposition

Pharmaceutical Science

English